Partner and firstname.lastname@example.org
- Raphaël joined Andera Partners in 2001.
- Since joining Andera he has worked on numerous investments, M&As and IPOs. Raphaël has in depth experience in all types of transactions gained both in banking and in Venture Capital.
- He sits on the boards of ImCheck, Amolyt Pharma, Poxel, Grey Wolf Therapeutics, Enyo Pharma, Dynacure, Artios, AM Pharma and Exciva. He was also a board member of Reviral, Axonics Modulation Technologies, Novagali Pharma, Pangenetics, Chase Pharmaceuticals, Oncoethix and Vessix Vascular until their acquisition by large pharmaceutical or medical device companies.
- Raphaël began his career in London, where he spent seven years in the healthcare and investment banking industries. He was first part of the finance department of Générale de Santé International in London, the largest private hospitals group in the UK, where he held treasury and investment analysis functions.
- He subsequently worked in the healthcare groups of the Investment Banking divisions of Salomon Smith Barney (1996-1999) and Goldman Sachs (1999-2001). During his years in investment banking, Raphaël participated in many M&A and capital raising deals within pharmaceuticals, medical devices, biotechnology and services companies.
- Raphaël graduated from the French business school HEC in 1993 and received a Master’s in Applied Economics from Institut d’Etudes Politiques in 1994.
20 years to sow
Investments of Raphaël
Novel enzymatic therapy for solid and liquid tumours
Small molecules to increase tumor detection by the immune system
Electrostimulation device for stress incontinence
New generation of antibody-based immunotherapy for the treatment of cancer and autoimmune diseases
Developing therapeutic peptides for rare endocrine and related diseases
Petites molécules pour le traitement de l’hépatite B chronique et de la NASH
Recombinant protein for the treatment of Sepsis-Associated Acute Kidney Injury
Antisense nucleotides for the treatment of neuromuscular rare disorders
Small molecules for the treatment of cancer
Small molecule for the treatment of behavioral and psychological symptoms of dementia in AD
Small molecule for the treatment of progressive multiple sclerosis
Small molecules as a therapeutic treatment for RSV infection
Neuromodulation technology for the treatment of incontinence
Development of small molecules for the treatment of Type 2 diabetes
Novel approach to increase efficacy and safety of marketed Alzheimer's drugs
Small molecules for haematological cancer treatment
The team andera Life Sciences
Jan Van den Bossche
Raymond W. Cohen
Natali Romero Barrios